China Elderly Valve Disease Study III (China-DVD3 Study)

ConditionsHeart Valve Diseases Moderate to Severe Valve Disease in the Elderly

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age60+

SponsorYongjian Wu, MD, PhD

About this trial

This study aims to conduct a second round of multicenter, prospective registry research targeting elderly patients with valvular heart disease, to understand the current status of interventions for patients with valvular heart disease. To systematically evaluate the distribution of types, clinical characteristics, interventions, and complications of elderly valvular heart disease, and to compare and analyze these with the China-DVD data from 2016, thereby revealing its evolutionary trends. By comprehensively considering various clinical characteristics such as different types of valvular lesions, treatment modalities, patient cardiac function, comorbidities, and blood test indicators, as well as multidimensional factors including psychological and lifestyle aspects, to deeply identify the key determinants influencing the treatment of elderly valvular heart disease patients in China, and thus optimize and improve their individualized comprehensive management pathways.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

(1)Mitral stenosis : Valve area ≤1.5 cm², or mean pressure gradient ≥10 mmHg.

(2)Mitral regurgitation : Moderate and above regurgitation, or regurgitant jet width ≥ 3 mm, or regurgitant volume per beat ≥ 30 ml, or regurgitant jet area/left atrial area > 20%; or effective regurgitant orifice area (EROA) ≥ 20 mm²

(3)Aortic stenosis : Moderate and above, mean pressure gradient ≥ 20 mmHg, or peak jet velocity ≥ 3 m/s, or valve area ≤ 1.5 cm²

(4)Aortic regurgitation : Moderate and above regurgitation, or regurgitant jet width ≥ 3 mm, or regurgitant volume per beat ≥ 30 ml, or regurgitant fraction ≥ 30%, or jet width occupying ≥ 25% of the left ventricular outflow tract, or effective regurgitant orifice area (EROA) ≥ 10 mm²

Disqualifiers

Patients with mental illness who cannot cooperate with information collection and follow-up Patients have been enrolled in this study.

Trial population

This project is scheduled to be implemented from September to December 2026. It will consecutively enroll hospitalized patients with moderate and severe valvular heart disease across the original 69 national research centers of China-DVD, with the research protocol and definitions fully consistent with those in 2016.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

6,612 Participants

are grouped into 1 trial group

Group A: China elderly Valve Disease Study III (China-DVD3 study)

Trial outcomes

Primary outcomes

First valve intervention during this hospitalization

Underwent their first internal medicine intervention or surgical procedure during hospitalization for valvular heart disease in this study

Time frame

From enrollment to the end of treatment at 12 weeks

Secondary outcomes

1、Repeat valve intervention 2、Cardiovascular adverse events

1 、Repeat valve intervention : After the first valve intervention, the patient receives another valve surgical or interventional procedure due to valvular-related causes. 2、Cardiovascular adverse events : Any new-onset or recurrent cardiovascular disease, rehospitalization for cardiovascular reasons, and cardiac death, etc.

Time frame

From enrollment to the 12-month follow-up endpoint

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Yongjian Wu, MD, PhD

Lead sponsor

China National Center for Cardiovascular Diseases

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: